Cidara Therapeutics

Learn more about our long-acting antiviral drug-Fc conjugate (DFC) for #influenza, and the journey that led to our ongoing Phase 2b clinical trial, in this recent article from BioProcess Online: https://lnkd.in/gA2n-mTk

We’re presenting at this year’s IDWeek! Our two presentations will highlight clinical data on the safety, pharmacokinetics and prophylactic activity of our drug-Fc conjugate (DFC) asset for #influenza. Read more: https://lnkd.in/ewXxRHRn #IDWeek2024

Today we announced two presentations highlighting data on our #influenza drug-Fc conjugate (DFC) candidate at the 2024 OPTIONS XII conference in Brisbane, Australia. Read here for more information on our oral and poster presentations: https://lnkd.in/gtbxJp3J

Today we announced the first subjects dosed in our Phase 2b NAVIGATE trial to evaluate the efficacy and safety of our #flu drug-Fc conjugate (DFC) for the pre-exposure prophylaxis of influenza during the current flu season. Read more here: https://lnkd.in/gTB7i2Tb

We’re pleased to announce the appointment of Rick Bright, Ph.D., Philip Krause, MD, Mario Barro, Ph.D., and Frederick G. Hayden, MD, FACP to our Scientific Advisory Board. Learn more about these infectious disease experts and how they will help guide us as we continue to advance our drug-Fc conjugate for influenza: https://lnkd.in/gYyGMWiN

We’re pleased to welcome Jim Beitel, MBA to the team as chief business officer (CBO). Jim’s extensive business development, strategy, and operational experience will be invaluable during this pivotal time as we focus exclusively on advancing our Cloudbreak drug-Fc conjugate (DFC) pipeline. Read more about his appointment here: https://lnkd.in/g3ekjJpd

Our CEO, Jeffrey Stein, Ph.D., spoke with Luke Timmerman on The Long Run podcast about our Cloudbreak platform and novel drug-Fc conjugate (DFC) candidate that has the potential for universal protection against all seasonal and pandemic #influenza A and B strains. Listen to the full podcast here: https://lnkd.in/gBUZz32T

Did you know our first-in-class antiviral drug-Fc conjugate (DFC) candidate has demonstrated universal activity across #influenza A and B viruses, including potent activity against #H5N1 in preclinical studies? Read more here: https://bit.ly/3XgCzXA

Today, we announced that we will be presenting a poster at ASM Microbe 2024, taking place from June 13-17, 2024, at the Georgia World Congress Center in Atlanta. Read the full press release here: https://lnkd.in/gXwyyz2n American Society for Microbiology

Read more about our recent $240M private placement financing led by RA Capital and reacquisition of CD388, our lead drug-Fc conjugate (DFC) candidate, in this blog post from Laura Tadvalkar, Managing Director on the Venture Team at RA Capital: https://brnw.ch/21wJhPq